The two companies in March began the launch of the mylife CamAPS FX app for automated insulin delivery on iOS platforms. In combination with the mylife YpsoPump, the offering enables people with type 1 diabetes to discreetly manage their therapy using an iPhone.
Ypsomed and CamDiab began their launch in Sweden for a pilot phase. After success there, the companies say they began a rollout in Austria, Denmark, Finland, Germany, Ireland, Luxembourg, Norway, Switzerland, and the UK. As of today, the companies now offer it in Australia, Belgium, Czechia, France, Italy, the Netherlands, New Zealand, Poland, and Spain. They previously said they hoped to bring it to Canada in the wider rollout as well.
FDA approved CamDiab’s mylife CamAPS FX app last May but the companies provided no details on an iOS rollout in the U.S.
The mylife CamAPS FX on iOS has full compatibility with leading continuous glucose monitors (CGMs). Those include the FreeStyle Libre 3 and Libre 3 Plus from Abbott and the Dexcom G6 so customers can use their preferred device.
With this rollout, Ypsomed and CamDiab also made the mylife Cloud data sharing function available on the app. This feature enables the secure sharing of therapy and glucose data with healthcare professionals and caregivers. The companies say it enhances support and remote diabetes management.
“Our goal is to simplify life for people with diabetes. The very positive feedback on our integrated, intuitive AID system, mylife Loop, shows that it is truly making a difference,” said Sébastien Delarive, chief business officer, Diabetes Care at Ypsomed.
